表紙
市場調査レポート

Jazz Pharmaceuticals plcの製品パイプライン分析

Jazz Pharmaceuticals plc - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 269905
出版日 ページ情報 英文 50 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.32円で換算しております。
Back to Top
Jazz Pharmaceuticals plcの製品パイプライン分析 Jazz Pharmaceuticals plc - Product Pipeline Review - 2015
出版日: 2015年04月22日 ページ情報: 英文 50 Pages
概要

当レポートでは、Jazz Pharmaceuticals plcにおける治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

Jazz Pharmaceuticals plcの基本情報

Jazz Pharmaceuticals plcの概要

  • 主要情報
  • 企業情報

Jazz Pharmaceuticals plc:R&Dの概要

  • 主な治療範囲

Jazz Pharmaceuticals plc:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • パートナー製品
    • パートナー製品/併用療法モダリティ

Jazz Pharmaceuticals plc:パイプライン製品の概況

  • 最終段階にあるパイプライン製品
    • 第III相にある製品/併用療法モダリティ
  • 治験段階にあるパイプライン製品
    • 第II相にある製品/併用療法モダリティ
    • 第I相にある製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品

Jazz Pharmaceuticals plc:開発段階が不明のパイプライン製品

  • 開発段階が不明の製品/併用療法モダリティ

Jazz Pharmaceuticals plc:薬剤プロファイル

  • asparaginase
  • inolimomab
  • SKL-N05
  • AZP-02
  • JZP-386

Jazz Pharmaceuticals plc:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Jazz Pharmaceuticals plc:最近のパイプライン動向

Jazz Pharmaceuticals plc:休止中のプロジェクト

Jazz Pharmaceuticals plc:開発が中止されたパイプライン製品

  • 開発が中止されたパイプライン製品のプロファイル
  • JZP-2
  • sodium oxybate

Jazz Pharmaceuticals plc:企業発表

Jazz Pharmaceuticals plc:本社と子会社の所在地

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC06968CDB

Summary

Global Markets Direct's, 'Jazz Pharmaceuticals plc - Product Pipeline Review - 2015', provides an overview of the Jazz Pharmaceuticals plc's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Jazz Pharmaceuticals plc's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Jazz Pharmaceuticals plc including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Jazz Pharmaceuticals plc's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Jazz Pharmaceuticals plc's pipeline products

Reasons to buy

  • Evaluate Jazz Pharmaceuticals plc's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Jazz Pharmaceuticals plc in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Jazz Pharmaceuticals plc's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Jazz Pharmaceuticals plc and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Jazz Pharmaceuticals plc
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Jazz Pharmaceuticals plc and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Jazz Pharmaceuticals plc Snapshot
    • Jazz Pharmaceuticals plc Overview
    • Key Information
    • Key Facts
  • Jazz Pharmaceuticals plc - Research and Development Overview
    • Key Therapeutic Areas
  • Jazz Pharmaceuticals plc - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Jazz Pharmaceuticals plc - Pipeline Products Glance
    • Jazz Pharmaceuticals plc - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • Jazz Pharmaceuticals plc - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Jazz Pharmaceuticals plc - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Jazz Pharmaceuticals plc - Drug Profiles
    • defibrotide
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • inolimomab
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SKL-N05
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • sodium oxybate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • asparaginase
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • JZP-386
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Nmers
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Oligotide
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Jazz Pharmaceuticals plc - Pipeline Analysis
    • Jazz Pharmaceuticals plc - Pipeline Products by Target
    • Jazz Pharmaceuticals plc - Pipeline Products by Route of Administration
    • Jazz Pharmaceuticals plc - Pipeline Products by Molecule Type
    • Jazz Pharmaceuticals plc - Pipeline Products by Mechanism of Action
  • Jazz Pharmaceuticals plc - Recent Pipeline Updates
  • Jazz Pharmaceuticals plc - Dormant Projects
  • Jazz Pharmaceuticals plc - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • JZP-2
      • sodium oxybate
  • Jazz Pharmaceuticals plc - Company Statement
  • Jazz Pharmaceuticals plc - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Jazz Pharmaceuticals plc, Key Information
  • Jazz Pharmaceuticals plc, Key Facts
  • Jazz Pharmaceuticals plc - Pipeline by Indication, 2015
  • Jazz Pharmaceuticals plc - Pipeline by Stage of Development, 2015
  • Jazz Pharmaceuticals plc - Monotherapy Products in Pipeline, 2015
  • Jazz Pharmaceuticals plc - Partnered Products in Pipeline, 2015
  • Jazz Pharmaceuticals plc - Partnered Products/ Combination Treatment Modalities, 2015
  • Jazz Pharmaceuticals plc - Pre-Registration, 2015
  • Jazz Pharmaceuticals plc - Phase III, 2015
  • Jazz Pharmaceuticals plc - Phase II, 2015
  • Jazz Pharmaceuticals plc - Phase I, 2015
  • Jazz Pharmaceuticals plc - Preclinical, 2015
  • Jazz Pharmaceuticals plc - Pipeline by Target, 2015
  • Jazz Pharmaceuticals plc - Pipeline by Route of Administration, 2015
  • Jazz Pharmaceuticals plc - Pipeline by Molecule Type, 2015
  • Jazz Pharmaceuticals plc - Pipeline Products by Mechanism of Action, 2015
  • Jazz Pharmaceuticals plc - Recent Pipeline Updates, 2015
  • Jazz Pharmaceuticals plc - Dormant Developmental Projects,2015
  • Jazz Pharmaceuticals plc - Discontinued Pipeline Products, 2015
  • Jazz Pharmaceuticals plc, Other Locations
  • Jazz Pharmaceuticals plc, Subsidiaries

List of Figures

  • Jazz Pharmaceuticals plc - Pipeline by Top 10 Indication, 2015
  • Jazz Pharmaceuticals plc - Pipeline by Stage of Development, 2015
  • Jazz Pharmaceuticals plc - Monotherapy Products in Pipeline, 2015
  • Jazz Pharmaceuticals plc - Pipeline by Top 10 Target, 2015
  • Jazz Pharmaceuticals plc - Pipeline by Top 10 Route of Administration, 2015
  • Jazz Pharmaceuticals plc - Pipeline by Top 10 Molecule Type, 2015
  • Jazz Pharmaceuticals plc - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top